Henlius (02696): HANSIZHUANG and Futanning New Indications Included in the National Reimbursement Drug List

Zhitong Finance APP News, Henlius (02696) announced that recently, Hansizhuang (serplulimab injection) was included in the Class B scope of the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)" for the first time, and the included indications cover all indications approved for marketing in China (excluding Hong Kong, Macao, and Taiwan regions of China, the same below). In addition, Fetuoning (voruciclib citrate capsules) had its second indication newly included in the National Medical Insurance Drug Catalog. The new version of the National Medical Insurance Drug Catalog will be officially implemented starting January 1, 2027.